2022
Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383)
DiSilvestro J, Dexter J, Haddad J, Beffa L, Raker C, Laprise J, Wilbur J, Clark M, Bradford L, Brown A, Hofstatter E, Dalela D, Toland M, Robison K, Stuckey A. Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383). Gynecologic Oncology 2022, 166: s195-s196. DOI: 10.1016/s0090-8258(22)01605-5.Peer-Reviewed Original ResearchFemale BRCA mutation carriersOral contraceptive pillsOvarian cancer screeningBRCA mutation carriersOvarian cancerMutation carriersGenetic testingGynecologic oncologistsContraceptive pillsCancer screeningExact testBRCA 1/2 mutation carriersCombined oral contraceptive pillBRCA mutation typeRisk-reducing surgeryPrimary care providersHigh-risk populationHalf of womenBRCA1/2 mutation carriersPossible early detectionFisher's exact testCross-sectional surveyGenetic counselorsCA 125Surgical options
2017
Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study
Forray A, Gilstad-Hayden K, Suppies C, Bogen D, Sofuoglu M, Yonkers KA. Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. Psychoneuroendocrinology 2017, 86: 96-103. PMID: 28926762, PMCID: PMC5659923, DOI: 10.1016/j.psyneuen.2017.09.012.Peer-Reviewed Original ResearchConceptsPre-pregnancy smokingSmoking levelsWeek 8Progesterone levelsPlacebo-controlled pilot trialDouble-blind studyOral micronized progesteroneSerious adverse eventsWeeks of gestationMain outcome measuresHalf of womenEndogenous progesterone levelsRelapse prevention strategiesCurrent pilot studyPreliminary findingsPostpartum smokersMicronized progesteronePlacebo groupProgesterone groupProgesterone replacementEligible womenSecondary outcomesAdverse eventsPoint prevalencePostpartum women
2016
Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment
Pluchino N, Wenger JM, Petignat P, Tal R, Bolmont M, Taylor HS, Bianchi-Demicheli F. Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment. Human Reproduction Update 2016, 22: 762-774. PMID: 27591248, DOI: 10.1093/humupd/dmw031.Peer-Reviewed Original ResearchConceptsSexual functionEndometriosis patientsPresence of dyspareuniaChronic pelvic painPresence of endometriosisEffect of surgeryOverall sexual functionEffect of endometriosisHalf of womenConsequence of treatmentQuality of lifeSystematic literature searchHealth care interventionsPelvic painDeep dyspareuniaSurgical treatmentMental comorbiditiesGynecologic disordersSexual painHormonal factorsHormonal treatmentMedical conditionsEndometriosisCoital painAdvanced stage
2013
Surgical preparation: are patients “ready” for stress urinary incontinence surgery?
Brubaker L, Litman H, Rickey L, Dyer K, Markland A, Sirls L, Norton P, Casiano E, Paraiso M, Ghetti C, Rahn D, Kusek J. Surgical preparation: are patients “ready” for stress urinary incontinence surgery? International Urogynecology Journal 2013, 25: 41-46. PMID: 23912506, PMCID: PMC3833875, DOI: 10.1007/s00192-013-2184-x.Peer-Reviewed Original ResearchConceptsStress urinary incontinence surgeryPatient Preparedness QuestionnaireUrinary incontinence surgeryQuality of lifeIncontinence surgerySurgical outcomesPre-operative urodynamic studyPost-operative satisfactionSecondary outcome measuresHalf of womenOverall incontinenceSUI surgeryUrge incontinenceClinical characteristicsUrodynamic studiesTreatment satisfactionVALUE trialUDI scorePatient preparednessPatient satisfactionOffice evaluationOutcome measuresPreparedness scoreSurgerySecondary analysisTBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).
Anders C, Deal A, Abramson V, Liu M, Storniolo A, Carpenter J, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin N, Marcom P, Van Poznak C, Stearns V, Melisko M, Smith J, Karginova O, Winer E, Perou C, Wolff A, Carey L. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). Journal Of Clinical Oncology 2013, 31: 515-515. DOI: 10.1200/jco.2013.31.15_suppl.515.Peer-Reviewed Original ResearchQuality of lifeBlood-brain barrierResponse rateCommon grade 3/4 adverse eventsCentral nervous system metastasesGrade 3/4 adverse eventsClinical benefit rateNervous system metastasesPhase II studyTumor response rateKaplan-Meier methodWhole brain RTHalf of womenBetter response rateSmall molecule anti-cancer agentTopoisomerase I inhibitorAdvanced TNBCCorrelative endpointsEligible ptsGermline BRCA1/2Measurable lesionsMedian TTPRadiation-naïveAnti-cancer agentsPrimary endpoint
2012
HPV Genotype Distribution in Cervical Intraepithelial Neoplasia among HIV-Infected Women in Pune, India
Mane A, Nirmalkar A, Risbud AR, Vermund SH, Mehendale SM, Sahasrabuddhe VV. HPV Genotype Distribution in Cervical Intraepithelial Neoplasia among HIV-Infected Women in Pune, India. PLOS ONE 2012, 7: e38731. PMID: 22723879, PMCID: PMC3378535, DOI: 10.1371/journal.pone.0038731.Peer-Reviewed Original ResearchConceptsCarcinogenic HPV genotypesHPV genotypesLow CD4HPV infectionCIN3 lesionsCommon HPV genotypesHPV genotype distributionMultiple HPV genotypesCombination antiretroviral therapyCervical intraepithelial neoplasiaCarcinogenic HPV infectionHalf of womenQuarter of womenHPV type detectionLifetime sexual partnersCarcinogenic HPVHPV16 detectionAntiretroviral therapyHPV genotypingComposite endpointOrder of prevalenceIntraepithelial neoplasiaCervical cancerHPV 16Observational study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply